STADA Arzneimittel AG (ETR:SAZ) received a €66.25 ($77.94) price objective from research analysts at Independent Research GmbH in a research note issued on Wednesday. The brokerage currently has a “neutral” rating on the stock.

A number of other research firms have also issued reports on SAZ. Warburg Research set a €60.00 ($70.59) target price on STADA Arzneimittel AG and gave the company a “neutral” rating in a report on Wednesday, July 5th. S&P Global set a €63.00 ($74.12) target price on STADA Arzneimittel AG and gave the company a “neutral” rating in a report on Wednesday, June 28th. Commerzbank Ag set a €66.00 ($77.65) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. Finally, Kepler Capital Markets set a €58.00 ($68.24) price target on STADA Arzneimittel AG and gave the stock a “sell” rating in a report on Wednesday, June 28th. Five equities research analysts have rated the stock with a hold rating, The stock currently has an average rating of “Hold” and a consensus target price of €64.90 ($76.35).

STADA Arzneimittel AG (ETR SAZ) opened at 63.696 on Wednesday. The firm has a market capitalization of €3.97 billion and a price-to-earnings ratio of 37.601. STADA Arzneimittel AG has a 12 month low of €41.40 and a 12 month high of €67.60. The company’s 50-day moving average price is €64.22 and its 200 day moving average price is €60.55.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/09/independent-research-gmbh-analysts-give-stada-arzneimittel-ag-etrsaz-a-66-25-price-target.html.

STADA Arzneimittel AG Company Profile

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.